

Prevnar and PCV-13 versus Synflorix[™] – waging war at 27th ESPID, Brussels with antibody levels

LONDON, UK----23rd June 2009----ExpertREACT. At the recent European Society For Pediatric Infectious Diseases, (ESPID) 2009 held in Brussels, it was clear that the battle between Wyeth's Prevnar franchise and GSK's newly licensed *pneumococcal* vaccine, Synflorix[™] had reached a new level of intensity. **VacZine Analytics** diagnoses each company marketing strategy in *pneumococcal* vaccines and current reaction.

*****NOTE***** This article is available only on a "pay per view" basis or to individual existing **VacZine Analytics** clients who have purchased **DiseaseINFOPACK** Non-typeable *Haemophilus influenzae* (CAT No: VADIP011), published March 2009.

Please visit www.vaccine-analytics/products-expertreact



References:



- 1) A World of Experience Makes the Difference. Wyeth Marketing Materials for Prevnar, Prevenar. May 2009. Available at: 27th ESPID, Brussels, June 9-13th, 2009.
- 2) Vesikari T., et al. Immunogenicity of the 10-valent *Pneumococcal* Non-typeable *Haemophilus influenzae* Protein D Conjugate Vaccine (PHiD-CV) Compared to the licensed 7vCRM Vaccine.
- 3) Siber GR., et al. Estimating the protective concentration of anti-*pneumococcal* capsular polysaccharide antibodies. *Vaccine*. 2007; 25:3816-3826.
- 4) Dagan R and Frascch C. Clinical Characteristics of a Novel 10-valent *pneumococcal* Non-typeable *Haemophilus influenzae* Protein D Conjugate Vaccine (PHiD-CV). *Ped Inf Dis*. 2009; 28 (4) S63-S65.
- 5) Assessment Report for Synflorix. European Medicines Agency. Evaluation of Medicines for Human Use. Procedure No. EMEA/H/C/000973.
- 6) Hicks LA., et al. For the Active Bacterial Core Surveillance Program for the Emerging Infections Program Network. Incidence of *pneumococcal* disease due to non-*pneumococcal* conjugate vaccine (PCV-7) in the United States during the era of widespread PCV-7 vaccination, 1998-2004. *J Infect Dis*. 2007; 196:1346-1354
- 7) Dagan R., et al. Introduction and expansion of multi-drug resistant *Streptococcus pneumoniae* serotype 19A clones causing acute otitis media in an unvaccinated population. *J Infect Dis*. In press.
- 8) GSK's Synflorix and Non-typeable *Haemophilus influenzae* – the secret to beating Wyeth? ExpertREACT Premium, published by **VacZine Analytics**, March 2009.
- 9) GSK Corporate Press Release 8th May, 2009. Available at: http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10051.htm. Accessed June 2009

VacZine Analytics[®] is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics[®] and "the spiral logo" are UK Registered Trademarks, 2009

© 2009 VacZine Analytics. All rights reserved.





VacZine Analytics^(R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics^(R) and "the spiral logo" are UK Registered Trademarks, 2009

© 2009 VacZine Analytics. All rights reserved.



VacZine Analytics[®]

Bringing life to vaccine strategy...

ExpertREACT[™]
